secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001437749-22-027044
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Diffusion Pharma rejects 'woefully inadequate' unsolicited offer; LifeSci launches proxy contest for board control
--------------------------------------------------------------------------------

- Director Eric Francois resigns effective Dec 16, 2022; Board reduces from 7 to 6 members.
- Company reports active bidding stage in strategic review; encouraged by response from multiple parties.
- Board rejects unsolicited offer from LifeSci client as woefully inadequate; encourages LifeSci to join process.
- LifeSci commences proxy contest to replace board with its own nominees ahead of Dec 30, 2022 annual meeting.
- Annual meeting of stockholders set for December 30, 2022, two weeks later than previously announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774922027044/0001437749-22-027044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774922027044/dffn20221113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-027044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer